Merck, Isomorphic Labs Enter Strategic Research Collaboration
By Connor Hart
Merck will collaborate with Isomorphic Labs, an AI-first drug design company, to develop new therapies.
The companies on Thursday said they will collaborate to discover therapeutic small-molecule candidates against an oncology target of strategic importance.
Isomorphic Labs will deliver molecular designs derived from its artificial-intelligence-enabled drug design engine.
Meanwhile, Merck will provide data sets on which the drug design engine will run. It will additionally be responsible for preclinical and clinical development, as well as manufacturing and commercialization of any products derived from the collaboration.
"By combining Merck's substantial internal data capabilities and discovery expertise with Isomorphic Labs' powerful modeling and compute capabilities, we aim to identify new ways to design and create better candidates faster," said George Addona, head of discovery for preclinical development and translational medicine at Merck Research Laboratories.
Under the terms of the agreement, Isomorphic Labs will receive an undisclosed, upfront payment from Merck.
Isomorphic Labs will additionally be eligible for payments based on the achievement of specified research, development, regulatory and commercial milestones, as well as tiered royalties on net sales. It will also receive an option to co-fund development activities, in return for elevated royalties.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
November 19, 2026 07:29 ET (12:29 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

The 10 Best Dividend Stocks

This Newly Undervalued Stock Has Plenty of Growth Ahead

